☆ 4.5 Letter

Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma

BONE MARROW TRANSPLANTATION (2021)

Get Full Text
Add to Collection

Journal

BONE MARROW TRANSPLANTATION
Volume 56, Issue 3, Pages 683-685

Publisher

SPRINGERNATURE
DOI: 10.1038/s41409-020-01029-4

Keywords

-

Categories

Biophysics Oncology Hematology Immunology Transplantation

Funding

  1. Takeda Pharmaceutical Company
  2. Spectrum Pharmaceuticals
  3. Astellas Pharma

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients

Michael Boyiadzis, Mei-Jie Zhang, Karen Chen, Hisham Abdel-Azim, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Talha Badar, Sherif M. Badawy, Minoo Battiwalla, Nelli Bejanyan, Vijaya Raj Bhatt, Valerie Brown, Paul Castillo, Jan Cerny, Edward A. Copelan, Charles Craddock, Bhagirathbhai Dholaria, Miguel Angel Diaz Perez, Christen L. Ebens, Robert Peter Gale, Siddhartha Ganguly, Lohith Gowda, Michael R. Grunwald, Shahrukh Hashmi, Gerhard C. Hildebrandt, Madiha Iqbal, Omer Jamy, Mohamed A. Kharfan-Dabaja, Nandita Khera, Hillard M. Lazarus, Richard Lin, Dipenkumar Modi, Sunita Nathan, Taiga Nishihori, Sagar S. Patel, Attaphol Pawarode, Akshay Sharma, Melhem Solh, John L. Wagner, Trent Wang, Kirsten M. Williams, Lena E. Winestone, Baldeep Wirk, Christopher S. Hourigan, Mark Litzow, Partow Kebriaei, Marcos de Lima, Kristin Page, Daniel J. Weisdorf

Summary: We investigated the impact of the number of induction/consolidation cycles on the outcomes of adult AML patients who received allo-HCT between 2008 and 2019. Our findings suggest that the number of induction cycles to complete remission (CR) has an impact on overall survival (OS) in patients who received myeloablative conditioning, with better OS observed in patients who achieved CR after 1 cycle compared to those who required 2 cycles or more. In contrast, the number of induction cycles did not affect OS in patients who received reduced-intensity conditioning. Consolidation therapy prior to allo-HCT was associated with improved OS in patients who achieved CR after 1 cycle. The presence of detectable minimal residual disease (MRD) at the time of allo-HCT did not impact outcomes in myeloablative allo-HCT, but was associated with an increased risk of relapse in reduced-intensity allo-HCT. Allo-HCT in patients with primary induction failure had significantly worse OS compared to allo-HCT in patients who achieved CR after 1-3 cycles.

LEUKEMIA (2023)

Add to Collection
Article Oncology

Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia

Talha Badar, Mark R. Litzow, Rory M. Shallis, Anand Patel, Antoine N. Saliba, Madelyn Burkart, Jan P. Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin Abaza, Adam Duvall, Danielle Bradshaw, Vamsi Kota, Shira Dinner, Aaron D. Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah

Summary: Although the clinical outcomes of TP53-mutated AML patients are generally poor, some patients eligible for curative-intent therapies may have better outcomes. This multicenter, retrospective study found racial disparities among TP53-mutated AML patients, with differences in treatment and outcomes between non-Hispanic White (NHW) and non-Hispanic Black (NHB) patients.

CANCER (2023)

Add to Collection
Article Hematology

The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms

Mark Gurney, Ismahene Chekkaf, Anmol Baranwal, Rami Basmaci, Bahga Katamesh, Patricia Greipp, James M. Foran, Talha Badar, Abhishek A. Mangaonkar, Kebede H. Begna, Naseema Gangat, Mrinal M. Patnaik, Mark R. Litzow, Mithun V. Shah, David S. Viswanatha, Rong He, Hassan B. Alkhateeb, Aref Al-Kali

Summary: ETV6 mutations are rare but recurrent somatic events that have negative prognostic implications in myelodysplastic syndrome and other myeloid neoplasms. This study examines the clinical and molecular characteristics of patients with deleterious ETV6 mutations, finding that they often co-occur with other mutations and occur in high-risk disease entities. The study highlights the need for further research on the role of ETV6 mutations in myeloid neoplasia.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection
Article Oncology

Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab Atallah, Rory Shallis, Antoine N. Saliba, Anand Patel, Jan P. Bewersdorf, Justin Grenet, Maximilian Stahl, Adam Duvall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Michal Kubiak, Shira Dinner, Aaron D. Goldberg, Yasmin Abaza, Guru Subramanian Guru Murthy, Vamsi Kota, Mark R. Litzow

Summary: We conducted a multi-center study to analyze factors predicting survival among TP53-mutated (m) AML patients receiving allogeneic hematopoietic stem cell transplant (allo-HSCT) in the recent era. The results showed that complete remission at day 100 post allo-HSCT and occurrence of chronic GVHD are significant predictors for better event-free survival (EFS) and overall survival (OS). Our findings suggest that allo-HSCT offers the best opportunity for long-term improvement in TP53m AML patients.

LEUKEMIA (2023)

Add to Collection
Letter Oncology

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases

Rimal Ilyas, Kristen McCullough, Talha Badar, Mrinal M. Patnaik, Hassan Alkhateeb, Abhishek Mangaonkar, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat

BLOOD CANCER JOURNAL (2023)

Add to Collection
Review Medicine, Research & Experimental

Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era

Talha Badar, Hassan Alkhateeb, Mahmoud Aljurf, Mohamed A. Kharfan-Dabaja

Summary: The combination of tyrosine kinase inhibitors (TKI) and induction regimens has significantly improved the outcome of Philadelphia chromosome positive (Ph') acute lymphoblastic leukemia (ALL). Recent data suggest that patients who achieve complete molecular remission within 3 months of TKI induction therapy can achieve comparable overall survival with or without allogeneic hematopoietic stem cell transplantation (allo-HSCT). Chemotherapy-free combinations, such as blinatumomab with ponatinib, have shown promising results in treatment-naive Ph' ALL patients.

CURRENT RESEARCH IN TRANSLATIONAL MEDICINE (2023)

Add to Collection
Article Biophysics

Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning

Shanze Arshad, Xi Fang, Kwang W. Ahn, Manmeet Kaur, Michael Scordo, Craig S. Sauter, Fateeha Furqan, Farrukh T. Awan, Mehdi Hamadani

Summary: This retrospective study evaluated the impact of thiotepa dose intensity on autologous stem cell transplant outcomes in adult primary central nervous system diffuse large B-cell lymphoma (PCNSL) patients. It was found that the intensity of thiotepa dose did not affect the outcomes of ASCT in PCNSL patients.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection
Article Hematology

Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients

Ahmad Nanaa, Rong He, James M. Foran, Talha Badar, Naseema Gangat, Animesh Pardanani, William J. Hogan, Mark R. Litzow, Mrinal Patnaik, Aref Al-Kali, Hassan B. Alkhateeb

Summary: Venetoclax is an FDA-approved selective inhibitor used for treating elderly or unfit AML patients. Combined with HMAs, it has shown impressive response rates in high-risk MDS and relapsed/refractory AML. However, its efficacy in treating mDDX41 MDS/AML patients remains uncertain due to lack of clinical experience.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection
Letter Hematology

IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: A multicentre experience

Naseema Gangat, Helen Ajufo, Maymona Abdelmagid, Omer Karrar, Kristen McCullough, Talha Badar, James Foran, Jeanne Palmer, Hassan Alkhateeb, Abhishek Mangaonkar, Andrew Kuykendall, Raajit K. Rampal, Ayalew Tefferi

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection
Review Oncology

Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms

Talha Badar, Yazan F. Madanat, Amer M. Zeidan

Summary: The majority of lower-risk myelodysplastic syndromes/neoplasms patients present with anemia. Historically, they were treated with erythropoiesis-stimulating agents (ESA) but with modest responses. Recently, luspatercept has shown better responses compared with ESAs in treatment-naive patients and imetelstat in patients refractory to ESAs. Other evaluated novel compounds have not yet shown meaningful efficacy. More needs to be done to improve outcomes, and participation in clinical trials evaluating novel therapies should be encouraged. Improving prognostication and serial monitoring will help identify high-risk patients for appropriate management.

FUTURE ONCOLOGY (2023)

Add to Collection
Article Oncology

U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity

Talha Badar, Yenny A. Moreno Vanegas, Ahmad Nanaa, James M. Foran, Aref Al-Kali, Abhishek Mangaonkar, Hemant Murthy, Hassan B. Alkhateeb, David Viswanatha, Rong He, Mithun Shah, Cecilia Arana Yi, Mark R. Litzow, Naseema Gangat, Ayalew Tefferi, Mrinal M. Patnaik

Summary: This study investigates the genotypic and prognostic heterogeneity of U2AF1 mutations in myelofibrosis and myelodysplastic syndromes. The results suggest that U2AF1 mutations can co-occur with other mutations and have different impacts on prognosis. Concurrent mutations and specific U2AF1 mutation types were found to be associated with different prognostic outcomes.

BLOOD CANCER JOURNAL (2023)

Add to Collection
Article Oncology

Aggressive chronic lymphocytic leukemia masked by extensive marrow fibrosis

Hareem Farooq, Ke Li, Talha Badar

Summary: Chronic lymphocytic leukemia (CLL) is a common B-cell leukemia characterized by abnormal proliferation of non-functional B-lymphocytes. It can lead to complications such as anemia, thrombocytopenia, infections, and secondary malignancies. Bone marrow fibrosis is rarely associated with CLL, and in this case, it was found to be a rare complication of aggressive CLL. The successful treatment of CLL resolved the bone marrow fibrosis, highlighting the importance of understanding its etiology.

LEUKEMIA RESEARCH REPORTS (2023)

Add to Collection
Article Hematology

Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas

Alberto Mussetti, Abraham S. Kanate, Tao Wang, Meilun He, Mehdi Hamadani, Herve Finel, Ariane Boumendil, Bertram Glass, Luca Castagna, Alida Dominietto, Joseph McGuirk, Didier Blaise, Zafer Gulbas, Jose Diez-Martin, Steven G. E. Marsh, Sophie Paczesny, Shahinaz M. Gadalla, Peter Dreger, Mei-Jie Zhang, Stephen R. Spellman, Stephanie J. Lee, Yung-Tsi Bolon, Anna Sureda

Summary: When comparing the outcomes of using a haploidentical donor and a matched unrelated donor (MUD) for lymphoma patients receiving post-transplantation cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis, the study found that MUD had better results in terms of overall mortality, progression-free survival, nonrelapse mortality, platelet engraftment, acute grade 2-4 GVHD incidence, and chronic GVHD. However, there were no significant differences in terms of relapse and neutrophil engraftment. Therefore, if a MUD is available in a timely manner, it should be preferred over a haploidentical donor for lymphoma patients using PTCy-based GVHD prophylaxis.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Add to Collection
Article Hematology

TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q)

Ayalew Tefferi, Farah Fleti, Onyee Chan, Najla H. Al Ali, Aref Al-Kali, Kebede H. Begna, James M. Foran, Talha Badar, Nandita Khera, Mithun Shah, Devendra Hiwase, Eric Padron, David A. Sallman, Animesh Pardanani, Daniel A. Arber, Attilio Orazi, Kaaren K. Reichard, Rong He, Rhett P. Ketterling, Naseema Gangat, Rami Komrokji

Summary: In MDS patients with del(5q), therapy-related setting and TP53 variant allele frequency >=22% were identified as independent risk factors for survival. This information may inform treatment decision-making in MDS-del(5q).

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection
Article Hematology

Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia

Muhammad Bilal Abid, Noel Estrada-Merly, Mei-Jie Zhang, Karen Chen, David Allan, Christopher Bredeson, Mitchell Sabloff, Guru Subramanian Guru Murthy, Talha Badar, Shahrukh Hashmi, Mahmoud Aljurf, Mark R. Litzow, Partow Kebriaei, Christopher S. Hourigan, Wael Saber

Summary: For older patients with AML undergoing alloHCT, the use of younger MUDs is associated with decreased relapse risk and improved DFS compared with the use of older MSDs.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Add to Collection
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.